Presenting on June 26th at The Washington Mayfair Hotel
NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS.
TORONTO, ON / ACCESSWIRE / June 19, 2019 / MPX International Corporation (“MPX International“, “MPXI” or the “Company“) (CSE: MPXI; OTC PINK: MPXOF) announced it will host both a luncheon and cocktail hour at The Washington Mayfair Hotel in London on June 26th where it will provide attendees with a corporate update. It will also host a series of private one-on-one meetings with investors upon request.
MPX International has announced a number of significant milestones recently including:
- Completion of the acquisition of HolyWeed, a Swiss-based organic cannabis company
- Acquisition of a GMP-ready pharmaceutical facility in Malta and was awarded an LOI to receive a license to import, extract, produce and distribute medical cannabis products in Malta and other international markets
- Establishment of a cannabis joint venture with First Growth Holdings in South Africa
- Closed an oversubscribed non-brokered Private Placement offering for gross proceeds of $26.9M
- Strengthened its Medical Advisory Board with the appointment of Dr Charles Akle to guide European growth initiatives
“With the UK moving to legalize medical cannabis last November and much of Europe also following suit, MPX International is positioning itself to thrive in these emerging markets,” said W. Scott Boyes, Chairman, President and CEO of MPXI. “Our recent strategic milestones speak to this as we continue to expand our footprint globally. From our acquisition of HolyWeed in Switzerland and the new facility in Malta to our joint venture with First Growth Holdings in South Africa and the strengthening of our advisory board to guide our European growth initiatives, we are looking forward to connecting with investors to provide insight into the strategic growth plans we believe are going to drive value.”
The presentations will be webcast, with an accompanying PowerPoint presentation, on the MPX International website at http://mpxinternationalcorp.com/
All events are being hosted June 26, 2019 at:
The Washington Mayfair Hotel
5 Curzon Street, Mayfair London
Greater London W1J 5HB
T: + 44(0) 20 7499 7000
12:00 – 1:30 PM
Entrance on Clarges Street
RSVP: [email protected]
5:00 – 7:00 pm
Entrance on Clarges Street
RSVP: [email protected]
Private Investor Meetings:
Please contact Crystal Quast at the following email address to schedule a private investor meeting: [email protected].
About MPX International Corporation
MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.
Cautionary Statement Regarding Forward-Looking Information
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
For further information, please contact:
SOURCE: MPX International Corporation
View source version on accesswire.com: